HPV Impfleitlinie

Literatur

  1. Jahn I., Eberle A., Niehues C., Birn A., Horch K. Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37, Robert Koch-Institut; 2007
  2. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005 Apr; 6 (4): 204.
  3. Baseman J. G., Koutsky L. A. The epidemiology of human papillomavirus infections. J Clin Virol. 2005 Mar; 32 Suppl 1: S16-24.
  4. Bosch F., de Sanjosé S., Castellsagué X., Moreno V., Muñoz N. Epidemiology of human papillomavirus infections and associations with cervical cancer: New opportunities for prevention. In Papillomavirus Research: From Natural History To Vaccines and Beyond. M Campo, ed (Wymondham, Caister Academic Press). 2006: 19-39.
  5. Manhart L. E., Holmes K. K., Koutsky L. A., Wood T. R., Kenney D. L., Feng Q., et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis. 2006 Aug; 33 (8): 502-8.
  6. Partridge J. M., Koutsky L. A. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006 Jan; 6 (1): 21-31.
  7. Carter J. J., Koutsky L. A., Wipf G. C., Christensen N. D., Lee S. K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996 Nov; 174 (5): 927-36.
  8. Klug S. J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., Petry K. U., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007 May; 79 (5): 616-25.
  9. Petry K. U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho Gomes H., Holz B., et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003 May 19; 88 (10): 1570-7.
  10. Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl I., et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000 Nov 20; 89 (6): 529-34.
  11. Trottier H., Franco E. L. The epidemiology of genital human papillomavirus infection. Vaccine. 2006 Mar 30; 24 Suppl 1: S1-15.
  12. Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12; 338 (7): 423-8.
  13. Nobbenhuis M. A., Helmerhorst T. J., van den Brule A. J., Rozendaal L., Voorhorst F. J., Bezemer P. D., et al. Cytological regression and clearance of 47 high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001 Nov 24; 358 (9295): 1782-3.
  14. Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005 Mar; 32 Suppl 1: S7-15.
  15. Longworth M. S., Laimins L. A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004 Jun; 68 (2): 362-72.
  16. Durst M., Glitz D., Schneider A., zur Hausen H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology. 1992 Jul; 189 (1): 132-40.
  17. Demeter L. M., Stoler M. H., Broker T. R., Chow L. T. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirusinfected lesions. Hum Pathol. 1994 Apr; 25 (4): 343-8.
  18. Munger K., Howley P. M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002 Nov; 89 (2): 213-28.
  19. Bohmer G., van den Brule A. J., Brummer O., Meijer C. L., Petry K. U. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol. 2003 Jul; 189 (1): 118-20.
  20. Snijders P. J., van den Brule A. J., Meijer C. J. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003 Sep; 201 (1): 1-6.
  21. FUTURE II STUDY GROUP. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10; 356 (19): 1915-27.
  22. Munoz N., Bosch F. X., de Sanjose S., Herrero R., Castellsague X., Shah K. V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6; 348 (6): 518-27.
  23. Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kummer J. A., Shah K. V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep; 189 (1): 12-9.
  24. Statistisches Bundesamt. Gesundheitswesen, Todesursachen in Deutschland 2004. Fachserie 12 / Reihe 4, Statistisches Bundesamt; 2005
  25. Richart R. M. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1968; 10: 748-84.
  26. Hampl M., Sarajuuri H., Wentzensen N., Bender H. G., Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006 Dec; 108 (6): 1361-8.
  27. Petry K. U., Bohmer G., Iftner T., Davies P., Brummer O., Kuhnle H. Factors associated with an increased risk of prevalent and incident grade III cervical intraepithelial neoplasia and invasive cervical cancer among women with Papanicolaou tests classified as grades I or II cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2002 Jan; 186 (1): 28-34.
  28. Creasman W. T. Vaginal cancers. Curr Opin Obstet Gynecol. 2005 Feb; 17 (1): 71-6.48
  29. Cupp M. R., Malek R. S., Goellner J. R., Smith T. F., Espy M. J. The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol. 1995 Sep; 154 (3): 1024-9.
  30. Dillner J., Meijer C. J., von Krogh G., Horenblas S. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol Suppl. 2000; (205): 194-200.
  31. Rubin M. A., Kleter B., Zhou M., Ayala G., Cubilla A. L., Quint W. G., et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001 Oct; 159 (4): 1211-8.
  32. Frisch M., Fenger C., van den Brule A. J., Sorensen P., Meijer C. J., Walboomers J. M., et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res. 1999 Feb 1; 59 (3): 753-7.
  33. Fox P. A. Human papillomavirus and anal intraepithelial neoplasia. Curr Opin Infect Dis. 2006 Feb; 19 (1): 62-6.
  34. Gross G., Barrasso R. Human Papillomavirus Infection. A Clinical Atlas. Wiesbaden, Berlin: Ullstein-Mosby; 1997; ISBN: 3-86126-117-0.
  35. Gross G., Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol. 2004 Feb; 193 (1): 35-44.
  36. Gross G., Ikenberg H., Gissmann L., Hagedorn M. Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol. 1985 Aug; 85 (2): 147-52.
  37. Lacey C. J. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005 Mar; 32 Suppl 1: S82-90.
  38. Gross G., Ikenberg H., Petry K. U., Pfister H., Schneede P., Schofer H., et al. [Condyloma acuminata and other HPV-associated diseases of the genitals, anus and urethra]. Hautarzt. 2007 Feb; 58 (2): 179-86.
  39. Krogh von, Lacey C. J., Gross G., Barrasso R., Schneider A. European Course on HPV Associated Pathology (ECHPV), European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. Int J STD AIDS. 2001; 12 Suppl 3: 40-7.
  40. Lowy D. R., Howley P. M. Papillomavirus replication. In Fields Virology, 1th ed (Philadelphia, Lippincott Williams & Wilkins). 2001: 2231-64.
  41. Armstrong L. R., Preston E. J., Reichert M., Phillips D. L., Nisenbaum R., Todd N. W., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis. 2000 Jul; 31 (1): 107-9.
  42. Wiatrak B. J. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg. 2003 Dec; 11 (6): 433-41.
  43. Kreimer A. R., Clifford G. M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14 (2): 467-75.49
  44. Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram P., et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003 Dec 3; 95 (23): 1772-83.
  45. D'Souza G., Kreimer A. R., Viscidi R., Pawlita M., Fakhry C., Koch W. M., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007 May 10; 356 (19): 1944-56.
  46. Mork J., Lie A. K., Glattre E., Hallmans G., Jellum E., Koskela P., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001 Apr 12; 344 (15): 1125-31.
  47. Smith E. M., Ritchie J. M., Summersgill K. F., Hoffman H. T., Wang D. H., Haugen T. H., et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004 Mar 17; 96 (6): 449-55.
  48. Reimers N., Kasper H. U., Weissenborn S. J., Stutzer H., Preuss S. F., Hoffmann T. K., et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007 Apr 15; 120 (8): 1731-8.
  49. Fakhry C., Gillison M. L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006 Jun 10; 24 (17): 2606-11.
  50. Smeets S. J., Hesselink A. T., Speel E. J., Haesevoets A., Snijders P. J., Pawlita M., et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007 Dec 1; 121 (11): 2465-72.
  51. Becker N. Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol. 2003 Dec; 129 (12): 691-702.
  52. Hakama M., Miller A. B., Day N. E. Screening for cancer of the uterine cervix. IARC Scientific Publications. 1986; 76 (Lyon).
  53. IARC. Cervix cancer screening. IARC Handbooks of Cancer Prevention. 2005; 10 (Lyon).
  54. European Medicines Agency. Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use 2006, Revision 4, Published 07/09/07 Online im Internet:
    URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm
  55. Villa L. L., Costa R. L., Petta C. A., Andrade R. P., Ault K. A., Giuliano A. R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol. 2005 May; 6 (5): 271-8.
  56. Block S. L., Nolan T., Sattler C., Barr E., Giacoletti K. E., Marchant C. D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 Nov; 118 (5): 2135-45.
  57. Giannini S. L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006 Aug 14; 24 (33-34): 5937-49.50
  58. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995 Jun; 69 (6): 3959-63.
  59. Harper D. M., Franco E. L., Wheeler C., Ferris D. G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19; 364 (9447): 1757-65.
  60. Fife K. H., Wheeler C. M., Koutsky L. A., Barr E., Brown D. R., Schiff M. A., et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004 Jul 29; 22 (21-22): 2943-52.
  61. Robert Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung. Epidemiologisches Bulletin. 12, 2007
  62. Garland S. M., Hernandez-Avila M., Wheeler C. M., Perez G., Harper D. M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10; 356 (19): 1928-43.
  63. Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Barr E., Alvarez F. B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21; 347 (21): 1645-51.
  64. Mao C., Koutsky L. A., Ault K. A., Wheeler C. M., Brown D. R., Wiley D. J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006 Jan; 107 (1): 18-27.
  65. Paavonen J., Jenkins D., Bosch F. X., Naud P., Salmeron J., Wheeler C. M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 Jun 30; 369 (9580): 2161-70.
  66. Villa L. L., Costa R. L., Petta C. A., Andrade R. P., Paavonen J., Iversen O. E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 Dec 4; 95 (11): 1459-66.
  67. Harper D. M., Franco E. L., Wheeler C. M., Moscicki A. B., Romanowski B., Roteli-Martins C. M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial. Lancet. 2006 Apr 15; 367 (9518): 1247-55.
  68. Joura E. A., Leodolter S., Hernandez-Avila M., Wheeler C. M., Perez G., Koutsky L. A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19; 369 (9574): 1693-702.
  69. Giroglou T., Sapp M., Lane C., Fligge C., Christensen N. D., Streeck R. E., et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001 Feb 8; 19 (13-14): 1783-93.51
  70. Smith J. F., Brownlow M., Brown M., Kowalski R., Esser M. T., Ruiz W., et al. Antibodies from Women Immunized with Gardasil ((R)) Cross-Neutralize HPV 45 Pseudovirions. Hum Vaccin. 2007 Jul-Aug; 3 (4): 109-16.
  71. MSD sanofi pasteur. Fachinformation Gardasil, August 2007 Online im Internet: URL: http://www.fachinfo.de/data/fi/jsearch?praep
  72. GlaxoSmithKline. Fachinformation Cervarix, September 2007 Online im Internet: URL: http://www.fachinfo.de/data/fi/jsearch?praep
  73. Petry K.U., Hillemanns P., Gieseking F., Littlewood K.J., Büsch K., Breugelmans J.G. Direkte und indirekte Kostenbewertungen HPV-assoziierter Erkrankungen (Genitalwarzen und zervikale Läsionen ) in Deutschland, 15 Jahrestagung der Deutschen Gesellschaft für Pädiatrische Infektiologie, 2007, Basel, Poster P68.
  74. Hillemanns P., Petry K. U., McAllister R., Büsch K., Largeron N. Vortrag zu: HPV (6, 11, 16 & 18)-Impfung als Primärprävention bei HPV-bedingten Erkrankungen - eine Kosteneffektivitätsanalyse in Deutschland. (Informationsquelle: Sanofi MSD). 2007
  75. Parkin D. M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006 Jun 15; 118 (12): 3030-44.
  76. Emeny R. T., Wheeler C. M., Jansen K. U., Hunt W. C., Fu T. M., Smith J. F., et al. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002 Aug; 76 (15): 7832-42.
  77. Gross G. [Impact of prophylactic HPV vaccines on dermatology and venereology]. Hautarzt. 2007 Jun; 58 (6): 507-14.
  78. Gieseking F. Incidence, prevalence and costsof treating genital warts in the pre-HPV vaccine era in Germany. Value Health. 2005; 8: 64-5.
  79. Kreuter A., Brockmeyer N. H., Hochdorfer B., Weissenborn S. J., Stucker M., Swoboda J., et al. Clinical spectrum and virologic characteristics of anal intraepithelial neoplasia in HIV infection. J Am Acad Dermatol. 2005 Apr; 52 (4): 603-8.
  80. Roka S., Rasoul-Rockenschaub S., Roka J., Kirnbauer R., Muhlbacher F., Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int. 2004 Aug; 17 (7): 366-9.
  81. Busnach G., Piselli P., Arbustini E., Baccarani U., Burra P., Carrieri M. P., et al. Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc. 2006 Dec; 38 (10):3533-5.
  82. European Medicines Agency. Cervarix, European Public Assessment Report, EPARs for authorised medicinal products for human use 2007, Published 03/10/2007 Online im Internet: URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm
  83. Schwarz T. F., Dubin G. O. An AS 04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer in immunogenic and welltolerated in women 15-55 years old. Journal of Clinical Oncology, 2006 ACSO Annual Meeting Proceedings (Post-Meeting Edition). 2006 June 20; 24 (18 Suppl). 52
  84. Hernan M. A., Alonso A., Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology. 2006 Jul 25; 67 (2): 212-5.
  85. Gloster H. M., Jr., Roenigk R. K. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol. 1995 Mar; 32 (3): 436-41.
  86. Sawchuk W. S., Weber P. J., Lowy D. R., Dzubow L. M. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol. 1989 Jul; 21 (1): 41-9.
  87. Barrett W. L., Garber S. M. Surgical smoke: a review of the literature. Is this just a lot of hot air? Surg Endosc. 2003 Jun; 17 (6): 979-87.